Results 1,521-1,540 of 3,998 for speaker:Michael Harty
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Michael Harty: Does Mr. Flanagan wish to contribute?
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Michael Harty: I thank Mr Hennessy. I will now move to Deputy Kelly.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Michael Harty: The Deputy should conclude her questioning.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Michael Harty: I invite Professor Barry to respond first.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Michael Harty: We will have a brief answer from Mr. Hennessy and then we will have to move on.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Michael Harty: I appreciate that. The Deputy has made it very clear. Deputy Brassil is next.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Michael Harty: Perhaps the witnesses will bank those questions while Senator Colm Burke makes his contribution.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Michael Harty: Does that refer to committee recommendation No. 5 to appoint of an independent academic with knowledge of pricing and reimbursement to conduct a review of the current process and the role of orphan drug availability in Ireland? Is that the review to which Mr. Judge is referring to?
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Michael Harty: That recommendation was that it would be an independent academic, but what is being proposed by Mr. Judge is an internal review within the Department.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Michael Harty: With regard to the rare disease technology review group, are there terms of reference for the group that can be sent to the committee?
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Michael Harty: It is a review group. Does it make decisions or does it just review decisions?
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Michael Harty: It goes to the drugs group.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Michael Harty: The representatives who appeared before the committee this morning spoke about the patients' representatives on that committee. They felt they were hand-picked rather than elected. What is the process of choosing the patient representative?
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Michael Harty: Ms McGrath may not speak.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Michael Harty: They were chosen by invitation.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Michael Harty: How is the representative chosen from among those who respond?
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Michael Harty: I thank Deputy Durkan for his patience.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Michael Harty: The Deputy might be straying off topic.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Michael Harty: I thank the Deputy.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Michael Harty: Is Mr. Hennessy saying that the 2013 legislation would have to be amended to allow for collective bargaining?